U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute of General Medical Sciences (NIGMS) <http://www.nigms.nih.gov/>
For Immediate Release: Tuesday, September 7, 2010
CONTACT:
NIGMS Communications Office, 301-496-7301, <e-mail:info@xxxxxxxxxxxxx>, <e-mail:Alisa.machalek@xxxxxxx>
NIH EXPANDS NETWORK FOCUSED ON HOW GENES AFFECT DRUG RESPONSES
The National Institutes of Health plans to spend $161.3 million over the next five years to expand the Pharmacogenomics Research Network (PGRN), a nationwide collaborative of scientists focused on understanding how genes affect a person's response to medicines.
"Thanks to breakthroughs in genome sequencing technologies and our growing understanding of genetic variation among individuals, there has never been a better time to propel the field of pharmacogenomics," said NIH Director Francis S. Collins, M.D., Ph.D. "Through these studies, we are moving closer to the goal of using genetic information to help prescribe the safest, most effective medicine for each patient."
Spearheaded by the NIH's National Institute of General Medical Sciences (NIGMS) and launched in 2000, the PGRN has already identified gene variants linked to responses to medicines for different cancers, heart disease, asthma, nicotine addiction and other conditions.
The expanded network will continue research in these areas and move into new ones, including rheumatoid arthritis and bipolar disorder. Network scientists will also develop novel research methods and study the use of pharmacogenetics in rural and underserved populations.
The new awards include 14 scientific research projects and seven network resources. The resources will benefit PGRN scientists by:
-- offering deep DNA sequencing capacity by partnering with experts in this field
-- providing statistical analysis expertise
-- developing standardized terminology for pharmacogenomics research
-- piloting ways to learn about pharmacogenomics from de-identified medical records in health care systems
-- continuing and expanding a 2-year-old international collaboration with the Center for Genomic Medicine at the RIKEN Institute in Yokohama, Japan.
RESEARCH GROUPS
The PGRN research group projects are listed below alphabetically by principal investigator. Also included are the anticipated five-year total costs for each grant.
Kathleen M. Giacomini, University of California, San Francisco, $11.9 million, Pharmacogenomics of Membrane Transporters (the Global Alliance for Pharmacogenomics resource listed below is also associated with this award)
Julie A. Johnson, University of Florida, Gainesville, $9.8 million, Pharmacogenomic Evaluation of Antihypertensive Responses
John R. Kelsoe, University of California, San Diego, $6.4 million, Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder
Ronald M. Krauss, Children's Hospital Oakland Research Institute (Calif.), $9.4 million, Pharmacogenomics and Risk of Cardiovascular Disease (the Human Exome Resequencing resource listed below is also associated with this award)
Caryn Lerman, University of Pennsylvania, Philadelphia, and Rachel F. Tyndale, University of Toronto, $12 million, Pharmacogenetics of Nicotine Addiction Treatment
Robert M. Plenge, Brigham and Women's Hospital, Boston, $7.5 million, Genetic Predictors of Response to Anti-TNF Therapy in Rheumatoid Arthritis
Mark J. Ratain, Nancy J. Cox and M. Eileen Dolan, University of Chicago, $10.3 million, PAAR--Pharmacogenomics of Anticancer Agents Research Group
Mary V. Relling, St. Jude Children's Research Hospital, Memphis, Tenn., $8.6 million, PAAR4Kids--Pharmacogenomics of Anticancer Agents Research in Children
Dan M. Roden, Vanderbilt University School of Medicine, Nashville, Tenn., $12.4 million, Pharmacogenomics of Arrhythmia Therapy (two resources listed below-PGRN Statistical Analysis Resource and Pharmacogenomic Discovery and Replication in Very Large Populations-are also associated with this award)
Wolfgang Sadee, Ohio State University, Columbus, $9.1 million, Expression Genetics in Drug Therapy
Alan R. Shuldiner, University of Maryland, Baltimore, $11.4 million, Pharmacogenomics of Anti-Platelet Intervention-2 (PAPI-2) Study
Kenneth E. Thummel and Wylie G. Burke, University of Washington, Seattle, $10.2 million, Pharmacogenetics in Rural and Underserved Populations
Richard M. Weinshilboum, Mayo Clinic, Rochester, Minn., $11.2 million, Pharmacogenetics of Phase II Drug Metabolizing Enzymes (two resources listed below-Next Generation DNA Sequencing and Pharmacogenomic Ontology Network Resource-are also associated with this award)
Scott T. Weiss and Kelan G. Tantisira, Brigham and Women's Hospital, Boston, $9.8 million, Pharmacogenetics of Asthma Treatment
NETWORK RESOURCES
The PGRN resources are listed below along with their anticipated five-year grant total costs. The scientists leading each effort are listed alphabetically.
Global Alliance for Pharmacogenomics, $3.2 million
Kathleen M. Giacomini, University of California, San Francisco
Next Generation DNA Sequencing, $2.3 million
Richard Gibbs, Baylor College of Medicine, Houston
Next Generation Sequencing, $3.0 million
Elaine Mardis, Washington University, St. Louis
Human Exome Resequencing, $3.9 million
Deborah A. Nickerson, University of Washington School of Medicine, Seattle
PGRN Statistical Analysis Resource, $2.4 million
Marylyn Ritchie, Vanderbilt University, Nashville
Pharmacogenomic Discovery and Replication in Very Large Populations, $3.4 million
Dan M. Roden, Vanderbilt University Medical Center, Nashville
Pharmacogenomic Ontology Network Resource, $3.1 million
Christopher Chute, Mayo Clinic, Rochester
The PGRN is funded by nine NIH components: NIGMS; the National Heart, Lung, and Blood Institute; the National Cancer Institute; the National Institute on Drug Abuse; the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Human Genome Research Institute; the National Institute of Mental Health; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; and the Office of Research on Women's Health in the Office of the Director.
To arrange an interview with NIGMS Director Jeremy M. Berg, Ph.D., or Rochelle M. Long, Ph.D., director of the NIH Pharmacogenomics Research Network, contact the NIGMS Office of Communications and Public Liaison at 301-496-7301. For more information about the NIH Pharmacogenomics Research Network, go to <http://www.nigms.nih.gov/Initiatives/PGRN/>. Information about the Global Alliance for Pharmacogenomics is at <http://www.nigms.nih.gov/Initiatives/PGRN/GAP/>.
NIGMS is a part of NIH that supports basic research to increase our understanding of life processes and lay the foundation for advances in disease diagnosis, treatment and prevention. For more information on the Institute's research and training programs, see <http://www.nigms.nih.gov>.
The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
##
This NIH News Release is available online at:
<http://www.nih.gov/news/health/sep2010/nigms-07.htm>.
To subscribe (or unsubscribe) from this list, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
